Home・Akciju saraksts・DexCom Inc

DexCom Inc

Slēgts

SektorsVeselības aprūpe

86.95 -0.29

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

85.87

Max

87.73

Galvenie mērījumi
By Trading Economics
Ienākumi	50M 249M
Pārdošana	117M 1.3B
P/E Sektora vidējais	34.51 68.51
EPS	0.7
Peļņas marža	19.039
Darbinieki	11,000
EBITDA	52M 389M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+3.68% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 29. okt.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	4.6B 33B
Iepriekšējā atvēršanas cena	87.24
Iepriekšējā slēgšanas cena	86.95

Ziņu noskaņojums

By Acuity

21%

79%

64 / 340 Rangs Healthcare

DexCom Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 4. aug. 19:56 UTC

Dexcom Inc. shares are lower today, pulling back after reaching a session high. The broader market benefits from a significant decline in crude oil prices.

2026. g. 3. aug. 20:02 UTC

News

Social Media

Dexcom Inc. shares are higher following strong Q2 results and raised revenue guidance to $5.22 billion. Canaccord increased its price target to $90.

2026. g. 31. jūl. 20:04 UTC

News

Social Media

Dexcom Inc. shares are higher following analyst upgrades and strong earnings, with second-quarter revenue of $1.31 billion exceeding expectations and guidance raised to $5.22 billion.

2026. g. 30. jūl. 23:51 UTC

News

Social Media

Dexcom reported second-quarter revenue of $1.308 billion and adjusted EPS of $0.70, raising its fiscal year 2026 revenue guidance, with shares trading higher in after-market hours.

2026. g. 29. jūl. 23:41 UTC

Dexcom Inc is trading higher in after-market hours, supported by overall market strength. The asset remains above its 20-day moving average.

2026. g. 28. jūl. 20:06 UTC

News

Dexcom shares rise after UBS initiated coverage with a Buy rating. The stock is advancing since Monday's close of $73.37 amid positive sentiment in the Health Care Equipment sector.

2026. g. 27. jūl. 19:06 UTC

News

Dexcom Inc. gains Health Canada approval for its Dexcom G7 continuous glucose monitoring system, boosting marketability and user adoption amid positive analyst sentiment.

2026. g. 24. jūl. 15:22 UTC

Dexcom Inc's shares are higher today, driven by gains in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

2026. g. 22. jūl. 20:01 UTC

Dexcom Inc. shares are lower today, continuing a decline since Tuesday. Earlier, the stock briefly rose before pulling back.

2026. g. 21. jūl. 19:26 UTC

Dexcom Inc is trading lower, continuing a trend of three consecutive declines. The stock reached a session low earlier today before a slight recovery.

2026. g. 20. jūl. 19:22 UTC

Dexcom Inc shares are lower amid broader market declines and rising Treasury yields. The stock remains near the upper end of its one-month trading range.

Salīdzinājums

Cenas izmaiņa

DexCom Inc Prognoze

Cenas mērķis

By TipRanks

3.68% augšup

Prognoze 12 mēnešiem

Vidējais 90.52 USD 3.68%

Augstākais 112 USD

Zemākais 64 USD

Pamatojoties uz 23 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi DexCom Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

23 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 23 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam DexCom Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

64 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.